Bio-Rad Laboratories (NYSE:BIO) today said it is launching is blood-based immunoassay kit to identify COVID-19 antibodies.
The assay is currently undergoing clinical evaluation in several hospitals, but 700 samples of data have shown specificity above 99%.
After being infected with SARS-CoV-2, viral antigens stimulate the immune system to produce antibodies and fight the virus. Bio-Rad suggests the blood-based immunoassay kit can help clinicians determine if an individual has been infected by the virus and developed an immune response.
Get the full story on our sister site, Drug Delivery Business.